Embecta Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $199.9M
- Price
- $3.19
- % Change (Daily % change from the live per-ticker quote feed.)
- -5.34%
- Volume
- 1.4M
Quote data as of 6:08 AM ET
About
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Quick stats
Shares outstanding59.3M
Computed float58.6M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001872789
Websitehttps://www.embecta.com
AI Summary
AI-generated11h agominorneutrallegal litigationEMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
Rosen Law Firm issued a shareholder-solicitation notice naming EMBC; no new disclosure from the company itself.
The release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm on a contingency basis.
This is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.